Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, which has broad therapeutic potential [3] - Eledon is conducting preclinical and clinical studies in areas such as kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS) [3] Upcoming Events - David-Alexandre C. Gros, M.D., CEO, and Steven Perrin, Ph.D., President and CSO, will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, at 1:40 p.m. ET [1] - A webcast replay of the session will be available on the company's website under Events [2]